ID | 1201 |
Name of the vaccine | Shigella4V |
Microbe | Bacteria |
Disease name | Bacillary Dysentery (Shigellosis) |
Name of bacteria | Shigella genus |
Type of vaccine | Bioconjugate |
Nucleic acid content | DNA |
Age | 8 months to 50 years |
Description of the vaccine | Shigella-tetravalent vaccine. |
Name of the manufacturer | LimmaTech Biologics AG |
Name of the manufacturing country | Kenya |
Year of manufacture | 2022 |
Clinical Phase status | Clinical - Phase 1, Phase 2 |
Bacterial strain | Gram-negative bacteria. |
Efficacy | NA |
Vaccine formulation | NA |
Dosage | Two doses (for adults). Three doses (for children). |
Mechanism of action | NA |
Route of administration | NA |
Indications | NA |
Export | NA |
Approval | NA |
Adjuvant | With or without Aluminium |
Repurposing | NA |
Side effects of vaccine | NA |
Post vaccination | NA |
Dose type | Combination doses |
Interspecies transfer | NA |
PubMed identifier | NA |
Clinical trial number | NCT04056117 |
Reference | NA |
Other name | NA |
Additional Links | NA
|